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Abstract
Background: Maternal diabetes is a well-known risk factor for birth defects, such as heart defects
and neural tube defects. The causative molecular mechanisms in the developing embryo are
currently unknown, and the pathogenesis of developmental abnormalities during diabetic
pregnancy is not well understood. We hypothesized that the developmental defects are due to
alterations in critical developmental pathways, possibly as a result of altered gene expression. We
here report results from gene expression profiling of exposed embryos from a mouse diabetes
model.
Results: In comparison to normal embryos at mid-gestation, we find significantly altered gene
expression levels in diabetes-exposed embryos. Independent validation of altered expression was
obtained by quantitative Real Time Polymerase Chain Reaction. Sequence motifs in the promoters
of diabetes-affected genes suggest potential binding of transcription factors that are involved in
responses to oxidative stress and/or to hypoxia, two conditions known to be associated with
diabetic pregnancies. Functional annotation shows that a sixth of the de-regulated genes have
known developmental phenotypes in mouse mutants. Over 30% of the genes we have identified
encode transcription factors and chromatin modifying proteins or components of signaling
pathways that impinge on transcription.
Conclusion: Exposure to maternal diabetes during pregnancy alters transcriptional profiles in the
developing embryo. The enrichment, within the set of de-regulated genes, of those encoding
transcriptional regulatory molecules provides support for the hypothesis that maternal diabetes
affects specific developmental programs.
Background
Maternal diabetes disturbs embryonic development and
can cause diabetic embryopathy, with cardiovascular mal-
formations, neural tube defects and caudal dysgenesis as
the most characteristic congenital malformations [1,2].
Diabetes-induced dysmorphologies have been ascribed to
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increased apoptosis [3,4], perturbation of prostaglandin
synthesis and metabolism [5-7], deficiency in membrane
lipids [8-11], and generally altered metabolism in the
embryo [12]. Several studies have associated oxidative
stress with the maternal diabetic condition, and the
administration of anti-oxidants reduced the incidence of
developmental defects in experimental models of intrau-
terine exposure to diabetes [5,13-19]. However, it is
unclear how systemic metabolic disease results in particu-
lar developmental defects that are restricted to specific tis-
sues in diabetic embryopathy [20].
Growing evidence suggests that maternal diabetes alters
expression of developmental genes in the embryo, result-
ing in abnormal morphogenesis. Decreased expression of
Pax3, a gene involved in neural tube defects [21,22], was
found in embryos from diabetic mouse dams at gestation
day 8.5, with neural tube defects evident by day 10.5 [4].
Pax3 deregulation, presumably through oxidative stress
[23], is also associated with heart defects that involve neu-
ral crest cell derivatives [24]. We recently showed that Wnt
signaling is affected in diabetes-exposed mouse embryos
[25]. These findings support the notion that diabetic preg-
nancy leads to altered expression of molecules that play
key roles in patterning and development of embryonic tis-
sues, implicating altered transcriptional regulation as a
potential pathogenic mechanism in diabetic embryopa-
thy. In order to identify genes and pathways affected by
maternal diabetes, we performed gene expression profil-
ing of diabetes-exposed mouse embryos using oligonucle-
otide microarrays.
Results and discussion
Animal model of diabetic embryopathy
Mouse embryos were isolated from diabetic or control
dams at embryonic day 10.5 (E10.5) because at this stage
neural tube defects are easily detectable. The frequency of
NTDs in diabetes-exposed embryos was approximately
17% (16/96 diabetes-exposed embryos) compared to 0%
in normal pregnancies (0/220). Except where noted, no
malformed embryos were used for gene expression stud-
ies. We found no significant differences in litter size or
number of resorbed embryos between diabetic (n = 11)
and non-diabetic pregnancies (n = 10; P = 0.07). We also
did not detect any developmental delay in apparently
unaffected diabetes-exposed embryos; their morphologi-
cal appearance, i.e. features of brain development, limb
development, and somite numbers were commensurate
with developmental age (Kruger et al., manuscript in
preparation). All experiments used the FVB inbred strain.
We here report the results from two independent expres-
sion profiling experiments (Figure 1), using individual
embryo samples in Experiment I and and a pooling strat-
egy in Experiment II.
Experimental approaches to determine gene expression profiles of normal and diabetes-exposed embryos Figure 1
Experimental approaches to determine gene expression profiles of normal and diabetes-exposed embryos. 
Panels A and B depict the two independent microarray experiments. Panels C and D depict expression profiles where each 
colored vertical line represents the expression signal for one gene and row represent individual embryos (Exp. I) or samples 
(Exp. II). Red represents increased expression, blue reflects decreased expression, and intermediate colors represent minor 
changes (the color range was chosen along an arbitrary scale). Using a hierarchical clustering algorithm (with euclidean distance 
metric and centroid linkage rule, as implemented in GeneSpring), these graphic representations shows that expression profiles 
for embryos exposed to maternal diabetes differ considerably from control unexposed embryo profiles.BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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Gene expression profiling in embryos exposed to diabetes
In Experiment I, we surveyed the expression profiles of 2
control and 5 diabetes-exposed embryos. In an initial
comparison of expression levels between control and dia-
betes-exposed embryos, 302 probe sets passed the "fold-
change>2" criterion, and their expression profiles were
visualized using hierarchical clustering (Figure 1, Panel
C). Control embryos exhibited profiles similar to each
other, and differences to the expression profiles of indi-
vidual diabetes-exposed embryos are visually obvious.
These results support the hypothesis that maternal diabe-
tes affects gene expression in the exposed embryos.
This survey covered about 14000 genes, and after applica-
tion of the analysis criteria (see Methods for details), we
identified 126 genes (~1% of the total) with expression
levels that were changed in diabetes-exposed embryos by
more than 2-fold relative to controls (Table 1; for full gene
names and accession numbers, see Additional File 1). An
additional 378 genes displayed expression differences
between 1.5- and 2-fold (data not shown). The majority
(83%) of the 126 genes we identified were expressed at
lower levels in diabetes-exposed compared to control
embryos, and this was reflected in the larger dataset as
well (72.8% of the additional 378 genes were decreased in
expression). This decreased gene expression was not the
result of developmental delay, since the morphology of
diabetes-exposed embryos was stage-appropriate.
Validation of microarray by quantitative real-time PCR
Changes in gene expression detected by microarray were
validated by quantitative real time PCR (Q-RT-PCR) for
selected genes with potential relevance to diabetes or
embryonic development (Table 2). Embryo samples were
from different pregnancies than those employed for the
microarray studies, and only embryos were used that
appeared morphologically normal. Of all genes assayed,
16 exhibited differential expression in the Q-RT-PCR
assay, confirming the microarray results in independent
embryo samples. Three genes exhibited no differences,
and seven genes were differentially expressed in both
assays (P < 0.05); however, the change occurred in oppo-
site directions. The discrepancies were traced back to (i)
annotation problems: Hmga1, Lin28, Phip, (ii) different
length of 3'UTR sequences where location of the microar-
ray probe would not query all transcripts arising from the
respective genes: Sema3a, Rod1, Slc2a1, or (iii) alternative
splicing: Ogt, Tfrc [26], Creb1 [27]. The Q-RT-PCR assays
were designed to specifically amplify a region of the tran-
script different from that covered by the microarray probe
in order to obtain an independent measurement. For the
majority of genes we tested, the independent assay con-
firms the initial finding that expression levels are altered
in embryos exposed to maternal diabetes.
We cannot formally exclude altered mRNA stability as a
factor causing the observed changes in mRNA levels, but
it would be difficult to explain how the stability of rela-
tively few transcripts could be altered in a selective fash-
ion. Rather, we find that many transcription factor genes
are down-regulated in their expression in diabetes-
exposed embryos, and this trend is also reflected in the
group of genes with 1.5- to 2-fold differences in expres-
sion; most likely therefore, the observed lower levels of
Table 1: Genes affected by maternal diabetes classified by cellular function. see Additional file 1
Functional category # of genes % of total Gene Symbol
Transcription factors 15 12 Bcl11a, Cited4, Creb1, Crsp2, Hif1a, Klf9, Lin28, Nsd1, Rb1cc1, Rnf14, Zfa, Zfp60, Zfp294, 
Zfp385, 2610020O08Rik
DNA-binding/chromatin 8 6 Atrx, Baz1b, Exod1, Hist1h2bc, Hmga1, Msl31, Setdb1, Top2b
Signal transduction 15 12 Ap1g1, Arid4b, Gad1, Grb10, Mapk10, Phip, Pik3c2a, Pkia, Ptp4a3, Ptprs, Rabgap1, Rp2h, 
Stam2, Ywhag, Zcsl3
Cell surface, incl. receptors 13 10 Agtr2, Aplp2, Cxadr, Efnb2, Epha3, Ghr, Gpr65, Il6st, Itgav, Pdgfra, Ptprk, Sema3a, Tgfbr1
Extracellular matrix/adhesion 9 7 Adam10, Ctse, Hs6st2, Ndst1, Ogt, Pcdh18, Pxn, Sel1h, Twsg1
Cytoskeleton/microtubules 10 8 Dcx, Dnm1l, Epb4.1l2, Gmfb, Kif11, Mtap2, Sncg, Tubb2b, Tubb2c, Vcl
RNA-binding 7 6 Arl5a, Dcp1a, Pabpc1, Rnpc2, Rod1, Sfrs2, Syncrip
Transporter/channels 9 7 Abcb7, Aqr, Cacna2d1, Mbtps1, Slc2a1, Slc16a3, Slc25a22, Stx17, Tm9sf3
Metabolism/enzymes 6 5 Aldh18a1, Blvrb, Gmpr, Pfkl, Tnks2, Upp1
Lipid metabolism 6 5 Etnk1, Hdlbp, Scd2, Sgpl1, Sptlc1, Stom
Metal-ion homeostasis 3 2 LOC669660, Mt2, Tfrc
Protein catabolism 9 7 Arih2, Nedd4, Supt16h, Usp7, Usp12, Eif3s10, Gopc, Lin7c, Vps35
Cell cycle/apoptosis 3 2 Api5, Birc4, Kras
Other 6 5 Dysf, Ivns1abp, Pelp1, Plekha5, Trim2, Trim44
Unknown 7 6 Heatr1, BC067396, 1300007C21Rik, 6330503C03Rik, 6330527O06Rik, 6330578E17Rik, 
LOC640370
total 126 100BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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gene expression are due to diminished or deregulated
transcription.
Molecular classification of genes altered in response to 
maternal diabetes
The biological roles of many products encoded by the 126
diabetes-affected genes are known (Table 1 and Figure 2,
Panel A). Most intriguingly, the largest functional category
is comprised by transcription factors (15/126) and DNA-
binding molecules known to affect transcriptional regula-
tion (8/126), with both categories together comprising
18% of the identified genes. Thus, relative to the 7% of
genes in the mouse genome that encode transcription fac-
tors [28], we found transcription regulatory genes highly
overrepresented among our diabetes-affected genes. This
is also reflected in enrichment of this category in DAVID
annotation http://david.abcc.ncifcrf.gov/. A combined
22% of the genes encode cell surface receptors (10%) and
signal transduction molecules (12%) that ultimately con-
verge on transcription. The transcription factor Pax3,
which was previously identified as affected by maternal
diabetes [4] was not represented on the microarray, but
was changed as expected when assayed by Q-RT-PCR [25].
These results indicate that transcription factors and signal-
ing molecules are prominent targets for perturbation by
maternal diabetes, and that altered transcriptional regula-
tion plays a major role in the response of embryos to
intrauterine exposure to diabetic conditions.
Transcription regulation
If maternal diabetes deregulates cohorts of genes in the
developing embryo through shared pathways of transcrip-
tional regulation, one would expect (i) occurrence of com-
mon transcription factor binding sites (TFBS) in
regulatory regions associated with multiple genes, and (ii)
overrepresentation of such TFBS relative to other genes in
the genome. We therefore analyzed the promoter
sequences (5kb upstream of the transcription start) of our
diabetes-affected genes for the presence of TFBS. As
expected for genes with mostly broad expression patterns
[29], we found a diverse set of conserved motifs in the
upstream regions of these genes (see Additional file 2).
Table 2: Validation of microarray results by quantitative RT-PCR. 
Microarray qRT-PCR
Gene Symbol Fold change t-test (p-value) Fold change t-test (p-value)
Adam10* -2.37 0.0024 -1.56 0.035
Api5* -2.30 0.0004 -1.33 0.007
Atrx -2.15 0.0016 -1.33 0.046
Baz1b* -2.38 0.0012 -1.58 0.017
Cxadr* -2.00 0.0034 -1.38 0.0002
Dcx* -3.05 0.0001 -2.20 <0.0001
Efnb2* -2.04 0.0437 -1.72 0.010
Hif1a -2.52 0.0041 -1.49 0.011
Il6st -2.28 0.0198 -1.77 0.039
Mt2 3.45 0.0053 2.16 0.027
Mtap2 -3.02 0.0000 -1.98 0.0002
Pcdh18* -5.77 0.0017 -1.35 <0.0001
Pdgfra1 -2.01 0.0100 -1.42 0.018
Tgfβ r1 -3.26 0.0002 -1.89 0.010
Twsg1 -4.91 0.0002 -1.89 0.005
Vcl -2.37 0.0020 -2.03 0.002
Hmga1 2.13 0.0060 -2.14 <0.0001
Lin28* 2.00 0.0182 -1.30 0.032
Ogt 2.52 0.0310 -1.51 0.019
Slc2a1 2.15 0.0252 -1.68 0.012
Phip -2.76 0.0006 1.49 0.011
Rod1* -2.32 0.0004 1.20 0.041
Sema3a -2.05 0.0003 1.74 0.024
Creb1 -3.33 0.0007 1.05 ns
Cited4* 2.11 0.0026 -1.10 ns
Tfrc* -2.20 0.0023 1.11 ns
For each gene, the amplification rate was calculated from the linear range of the reaction, and diabetes-exposed embryos (n = 9 from 4 litters) were 
compared to 4 pools (4 litters) of mRNA from control embryos. In reactions for genes marked with *, the control group consisted of mRNA from 
individual embryos (n = 6 from 4 litters). All embryos were isolated at E10.5 and were morphologically normal. Negative values for "fold-change" 
indicate reduction of expression.BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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Intriguingly, there was prominent over-representation of
binding sites for the transcription factors FOXO1 and
FOXO4 (-Log(p) = 12.416 and -Log(p) = 10.544, respec-
tively), which are known to be involved in the response to
oxidative stress, and for HIF1 (-Log(p) = 10.219), which is
involved in the response to hypoxia. Out of 109 genes for
which results were returned, FOXO1 and FOXO4 sites
were enriched in 68% of the genes. NRF2 motifs were
found in 76 promoters, further supporting the notion that
oxidative stress may be involved in the response of diabe-
tes-exposed embryos. HIF1 motifs were enriched in pro-
moter regions of 22 genes (20.2%). These TFBS occur in
combinations with sites for other transcription factors
with a known role in responses to hypoxia, such as ATF4,
E2F1 and E2F4, EGR1, ETS1, IRF1, NfkappaB, SOX9, SP3,
and XBP1 (see Additional file 2 for references). Given the
proposed role of oxidative stress and hypoxia in the
pathogenesis of diabetic embryopathy [5,6,14,17,18,30],
it is striking that 97% of the genes affected by maternal
diabetes carry in their upstream regions potential binding
sites for transcription factors that are involved in
responses to oxidative stress and hypoxia.
Both conditions have been reported to be associated with
diabetic pregnancy [14,31], and would predict activation
of hypoxia-regulated pathways in the embryonic response
to diabetic conditions. Paradoxically, the expression of
Hif1α, a key regulator of embryonic responses to hypoxia
[32], was reduced in our diabetes-exposed embryos at
E10.5. In a post-hoc analysis of our microarray data with
specific focus on HIF1 target genes [33], 22 HIF1 targets
showed altered expression (fold-change >1.5) and passed
one of the t-tests; 9 genes passed both statistical filters
(details, see Additional file 3). Twenty HIF1-regulated
genes exhibited increased expression in diabetes-exposed
embryos, possibly reflecting an embryonic response to
increased hypoxia. Further support for this idea comes
from Hif1α message levels that are increased in diabetes-
exposed embryos at E8.5 and E9.5 (Figure 3), and this
increased Hif1α expression could be responsible for the
increased expression of HIF target genes at E10.5.
Together, these results implicate oxidative stress and
hypoxia pathways in deregulated gene expression in dia-
betes-exposed embryos and identify the molecular targets
of these pathways.
Functional roles of genes deregulated by maternal diabetes
Our identification of genes whose expression is affected
by exposure to maternal diabetes suggests that those genes
could be involved in the developmental defects in dia-
betic pregnancies. This notion is supported by qualitative
expression information (MGI) for 69 of these genes, with
62 detected in the embryonic CNS, and 35 in the embry-
onic cardiovascular system. With both CNS and heart fre-
quently being affected in diabetic embryopathy, genes
with abnormal expression in these tissues might contrib-
ute to pathogenesis of birth defects.
Functional data also support this hypothesis: most
remarkably, about one fourth of the diabetes-affected
genes are known genes for which a functional role in
embryonic development was established experimentally:
in knockout mutant mice, 35 of the genes we identified
have been shown, by genetics, to be required for mouse
embryonic development (Table 3 and Figure 3, Panel C;
references are given in Supplementary Table 4). This
implies that these genes, under conditions of maternal
diabetes but in the absence of genetic alterations, are sub-
ject to gene-environment interactions and respond to the
intra-uterine environment of a diabetic pregnancy. Defi-
ciencies in 15 of our genes (Agtr2, Cxadr, Dysf, Hif1a,
Il6st, Itgav, Pdgfra, Pxn, Sema3a, Tgfbr1, Vcl, Adam10,
Epha3, Efnb2, and Sfrs2) have been shown to cause cardi-
ovascular defects or disease in mouse models. In humans,
the risk for congenital heart disease is 2.8 times higher in
infants born to diabetic mothers compared to the off-
spring of non-diabetic mothers [2] with higher odds ratios
for specific malformations [34,35]. In light of this, it is
possible that down-regulation by maternal diabetes of
one or more of the genes we discovered could contribute
to abnormalities of the heart [36].
Central nervous system malformations occur in about 5%
of children born to diabetic mothers [35], which repre-
sents an up to 15-fold higher risk of over pregnancies
Expression of Hif1α during mouse embryogenesis Figure 2
Expression of Hif1α during mouse embryogenesis. 
Quantitative RT-PCR for Hif1α at various stages of develop-
ment normalized to expression levels of Pole4. n = number 
of individual embryos tested.BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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Classification of diabetes-affected genes by molecular function and function in vivo Figure 3
Classification of diabetes-affected genes by molecular function and function in vivo. Panel A depicts the representa-
tion of molecular classes of encoded products for the diabetes-affected genes identified in Experiment I. Panel B depicts the 
representation of molecular classes for the diabetes-affected genes identified in Experiment II. Genes encoding products with 
unknown function were omitted. Panel C depicts in vivo phenotypes based upon MGI annotation for genes identified in Exper-
iment I; Panel D depicts in vivo phenotypes for genes in Experiment II. Only knockout phenotypes (null and conditional) were 
included.
Table 3: In vivo function of genes affected in diabetes exposed embryos. 
Function # GeneSymbol
metabolic/growth defect 15 Ap1g1, Aplp2, Ghr, Grb10, Hmga1, Mapk10, Mbtps1, Mtap2, Nedd4, Ptprs, Scd2, Tnks2, Top2b, Upp1, Zfp385
diabetes 2 Ghr, Hmga1
embryonic 35 Abcb7, Adam10, Agtr2, Ap1g1, Aplp2, Bcl11a, Creb1, Cxadr, Dcx, Efnb2, Epha3, Gad1, Grb10, Hif1a, Il6st, Itgav, 
Kras, Mbtps1, Ndst1, Nedd4, Nsd1, Ogt, Pdgfra, Ptprs, Pxn, Scd2, Sema3a, Setdb1, Sfrs2, Slc2a1/Glut1ASa,, Tfrc, 
Tgfbr1, Top2b, Twsg1, Vcl
cardiovascular 15 Adam10, Agtr2, Cxadr, Dysf, Efnb2, Epha3, Hif1a, Il6st, Itgav, Pdgfra, Pxn, Sema3a, Sfrs2, Tgfbr1, Vcl
neural tube defects 7 Adam 10, Hif1a, Pdgfra, Tfrc, Tgfbr, Twsg1, Vcl
Information was obtained from GO annotations and hand curated with input from MGI and PubMed sources. All results are from knockout models, 
except for: a) Glut 1 antisense transgenic mice. References are provided in Additional file 4.BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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Table 4: Wnt-pathway genes affected by maternal diabetes. 
Control Exp. II
Mean (+/-SD) Mean (+/-SD) p-value fold-change Gene Symbol Gene Title
1450007_at 602 (± 141) 76 (± 23) 0.0031 -7.93 1500003O03Rik similar to EF-hand Ca2+ binding protein p22
1450056_at 423 (± 43) 103 (± 42) 0.0008 -4.12 Apc adenomatosis polyposis coli
1455231_s_at 326 (± 71) 97 (± 3) 0.0052 -3.36 Apc2 adenomatosis polyposis coli 2
1426966_at 1257 (± 52) 530 (± 52) 6.6-5 -2.37 Axin1 axin 1
1444031_at 17 (± 5) 47 (± 6) 0.0028 2.80 Camk2d calcium/calmodulin-dependent protein kinase II, 
delta
1417176_at 3354 (± 833) 1102 (± 385) 0.0132 -3.04 Csnk1e casein kinase 1, epsilon
1422887_a_at 3473 (± 351) 1625 (± 222) 0.0015 -2.14 Ctbp2 C-terminal binding protein 2
1430533_a_at 3643 (± 841) 333 (± 352) 0.0033 -10.95 Ctnnb1 beta-catenin
1458662_at 167 (± 35) 75 (± 18) 0.0152 -2.23 Daam1 dishevelled associated activator of 
morphogenesis 1
1450978_at 965 (± 42) 430 (± 40) 9.0-5 -2.24 Dvl1 dishevelled homolog 1
1417207_at 993 (± 91) 327 (± 46) 0.0004 -3.04 Dvl2 dishevelled homolog 2
1455220_at 181 (± 12) 76 (± 12) 0.0004 -2.39 Frat2 frequently rearranged in advanced T-cell 
lymphomas 2
1437284_at 2115 (± 66) 965 (± 32) 1.1-5 -2.19 Fzd1 frizzled homolog 1
1418532_at 1720 (± 389) 551 (± 193) 0.0096 -3.12 Fzd2 frizzled homolog 2
1450044_at 2329 (± 163) 884 (± 174) 0.0005 -2.63 Fzd7 frizzled homolog 7
1423348_at 419 (± 33) 188 (± 35) 0.0011 -2.23 Fzd8 frizzled homolog 8
1427529_at 136 (± 24) 57 (± 21) 0.0125 -2.40 Fzd9 frizzled homolog 9
1455689_at 485 (± 124) 204 (± 22) 0.0182 -2.37 Fzd10 frizzled homolog 10
1451020_at 434 (± 144) 156 (± 28) 0.0303 -2.79 Gsk3b glycogen synthase kinase 3 beta
1417409_at 1585 (± 117) 664 (± 114) 0.0006 -2.39 Jun Jun oncogene
1425795_a_at 1069 (± 122) 423 (± 92) 0.0018 -2.53 Map3k7 mitogen activated protein kinase kinase kinase 7
1452497_a_at 192 (± 85) 39 (± 4) 0.0353 -4.97 Nfatc3 nuclear factor of activated T-cells, calcineurin-
dependent 3
1423379_at 497 (± 87) 81 (± 9) 0.0012 -6.17 Nfatc4 nuclear factor of activated T-cells, calcineurin-
dependent 4
1419466_at 353 (± 31) 166 (± 5) 0.0005 -2.13 Nkd2 naked cuticle homolog 2
1448661_at 385 (± 42) 189 (± 47) 0.0057 -2.04 Plcb3 phospholipase C, beta 3
1439797_at 306 (± 67) 100 (± 27) 0.0078 -3.05 Ppard peroxisome proliferator activator receptor delta
1426401_at 1094 (± 85) 525 (± 41) 0.0005 -2.08 Ppp3ca protein phosphatase 3, catalytic subunit, alpha 
isoform
1427468_at 1103 (± 170) 207 (± 169) 0.0029 -5.32 Ppp3cb protein phosphatase 3, catalytic subunit, beta 
isoform
1450368_a_at 186 (± 53) 83 (± 16) 0.0321 -2.23 Ppp3r1 protein phosphatase 3, regulatory subunit B, 
alpha isoform (calcineurin B, type I)
1452878_at 366 (± 35) 172 (± 32) 0.0021 -2.13 Prkce protein kinase C, epsilon
1448695_at 242 (± 84) 70 (± 28) 0.0284 -3.44 Prkci protein kinase C, iota
1424287_at 190 (± 55) 34 (± 12) 0.0084 -5.53 Prkx protein kinase, X-linked
1451358_a_at 2310 (± 218) 1154 (± 250) 0.0038 -2.00 Racgap1 Rac GTPase-activating protein 1
1416577_a_at 5908 (± 412) 11936 (± 1884) 0.0056 2.02 Rbx1 ring-box 1
1423444_at 1347 (± 351) 657 (± 105) 0.0311 -2.05 Rock1 Rho-associated coiled-coil containing protein 
kinase 1
1425465_a_at 611 (± 128) 194 (± 73) 0.0080 -3.15 Senp2 SUMO/sentrin specific peptidase 2
1416594_at 722 (± 105) 300 (± 44) 0.0030 -2.41 Sfrp1 secreted frizzled-related protein 1
1422485_at 2828 (± 354) 1189 (± 425) 0.0068 -2.38 Smad4 MAD homolog 4
1434644_at 780 (± 274) 29 (± 15) 0.0090 -27.22 Tbl1x transducin (beta)-like 1 X-linked
1429427_s_at 221 (± 5) 460 (± 97) 0.0132 2.08 Tcf7l2 transcription factor 7-like 2, T-cell specific, 
HMG-box
1455592_at 1336 (± 506) 306 (± 101) 0.0258 -4.37 Vangl2 vang-like 2 (van Gogh homolog)
1448818_at 212 (± 68) 82 (± 16) 0.0326 -2.60 Wnt5a wingless-related MMTV integration site 5A
1420892_at 645 (± 120) 213 (± 15) 0.0035 -3.03 Wnt7b wingless-related MMTV integration site 7B
Components of the Wnt pathway were identified according to KEGG and GenMAPP annotation. Affymetrix probe ID numbers are given for 
representative probe sets. Means of signal intensities and standard deviations were rounded the next full figure; p-values were rounded to the 
fourth digit after the period except where otherwise indicated; fold-change values were rounded to the second digit after the period. Negative fold-
change values indicate reduced expression level in diabetes-exposed embryos.BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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unaffected by diabetes. Intriguingly, we found seven genes
affected by maternal diabetes that previously have been
associated with neural tube defects (NTD): Hif1a, Pdgfra,
Twsg1, Adam10, Tgfbr1, Tfrc, and Vcl (for references, see
Additional file 4). Thus, de-regulated expression of these
genes in diabetes-exposed embryos might predispose
embryos to neural tube defects. We also analyzed our
dataset from Experiment I for differences between the 5
embryos that were exposed to maternal diabetes, of which
two exhibited defective closure of the neural tube. In this
comparison, we identified only two genes (Etnk1, Gmfb)
that passed the criteria filter of >1.5-fold change and both
statistical significance tests. Both genes were detected in
the initial diabetes-exposed versus normal comparison;
we did not discover any genes that were uniquely altered
in NTD embryos, implying that differences between NTD-
affected and -unaffected individuals with regard to gene
expression are mostly quantitative. Our results are consist-
ent with the hypothesis that diabetes of the mother alters
expression of specific known heart-defect and neural-
tube-defect genes, and that these genes may be responsi-
ble for the birth defects in diabetic pregnancies.
Confirmation of major findings by a separate profiling 
experiment
Our intial survey employed embryo samples that came
from two pregnant females: one STZ-treated diabetic and
a control untreated dam. This presents the theoretical pos-
sibility that any differences between progeny of the two
dams reflect differences between pregnancies in addition
to diabetic state. Also, we used individual embryo sam-
ples, and this approach is likely to incur substantial varia-
bility in the data and thus understimation of molecular
changes. To address both concerns, we conducted Experi-
ment II, in which equal amounts of RNA was pooled from
three embryos of same gestational age into one sample,
with each embryo derived from a different dam; for the
diabetic as well as the control condition, we prepared
three such pools, respectively (Figure 1, Panel B). Taking
advantage of technical advances, these samples were proc-
essed and hybridized to the Affymetrix Mouse 430 2.0
chip, which surveys 39000 transcripts. Using the same
analysis criteria as before, we identified 2231 transcripts
of which 276 (12.37%) showed increased levels of expres-
sion in the diabetes-exposed samples, and 1955 (87.63%)
exhibited decreased expression compared to the controls
(Figure 1, Panel D). Thus, we confirm the general trend in
the results from Experiment I. Of the differentially
expressed transcripts, 179 lacked identifying features,
such as a name, RefSeq or ENSEMBLE IDs, or Unigene
Mm. cluster number; they also lacked any annotation
information. This left us with 2052 annotatable genes.
Classification by molecular functions revealed a distribu-
tion of molecular properties (Figure 3, Panel B) highly
similar to that in Experiment I (Figure 3, Panel A). Again,
genes encoding transcription factor and DNA-binding reg-
ulatory molecules were significantly enriched, accounting
for 16.3% of the deregulated genes; strong enrichment
was confirmed by DAVID annotation. Annotation for
function in vivo identified 1836 gene entries in MGI; for
1095 of those, phenotype information was not available.
However, 747 genes were associated with documented
phenotypes in mouse mutants, of which 388 are develop-
mental phenotypes by virtue of embryonic, neonatal, or
perinatal death of homozygous mutant offspring. Again,
the distribution of particular phenotypes in Experiment II
(Figure 3, Panel D) was very similar to that of Experiment
I (Figure 3, Panel C). Metabolic abnormalities were
reported for mutants of 46 genes, and evidence for abnor-
mal growth (pre- and post-natal) was obtained for 279
genes. Most notably, 161 genes are known to be associ-
ated with heart defects when mutated, and 112 genes are
known to play causal roles in neural tube defects. This is
only a fraction (35%) of the more than 300 NTD genes
contained in the MGI database (as of October 1, 2008).
Similarly, from the published collection of 170 mouse
mutants with neural tube defects [37] for which the
underlying molecular defect is known, 55 genes (32% of
170) were identified in Experiment II. Taken together,
these results indicate that maternal diabetes affects spe-
cific pathogenic pathways leading to NTDs. Except for two
genes, all NTD genes exhibited decreased expression on
the arrays. In summary, the main findings of the initial
microarray experiment were confirmed.
Indeed, of the 126 genes whose expression was altered by
more than 2-fold in Experiment I, 67 were also recovered
above the 2-fold change cut-off in Experiment II. Of the
378 probe sets with expression level altered between 1.5-
fold and 2-fold, 187 were shared. Thus, of the 504 probe
sets with altered expression in Experiment I, more than
half (254) were confirmed in Experiment II, providing
independent validation for the major results of the first
experiment. This 50% confirmation rate for independent
microarray experiments in the same biological paradigm
agrees well with similar findings for independent yeast
microarray results [38]. Thus, employing individual
embryo samples as well as a pooling strategy, we have
identified molecular targets in the embryo that respond to
maternal diabetes. Also noteworthy is that Experiment II
confirmed our earlier candidate gene studies that showed
components of the Wnt pathway altered in diabetes-
exposed embryos [25]. In fact, 43 genes with roles in Wnt
signaling are affected by maternal diabetes (Table 4); with
exception of Cank2d, Rbx1 and Tcf7l2 (which are upregu-
lated), the expression levels of all of these genes are
decreased in diabetes-exposed embryos compared to con-
trols. This finding provides further support for our
hypothesis that maternal diabetes affects specific develop-
mental programs.BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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Using mRNA from whole individual embryos allowed us
to survey a broad range of embryonic tissues that are
potentially affected by maternal diabetes. This approach
might have "missed" effects on genes that are expressed
only in small cell populations of the embryo. However, in
Experiment II, we identify 19 of the 47 published genes
that were found altered more than 1.5-fold in microarray
analysis of cranial neural tube tissue from diabetes-
exposed embryos with neural tube defects at E 11.5 [39],
and four of those genes are shared with Experiment I.
Concordance was found for increased expression of
Bnip3, and for decreased levels of En2, Hes6, Ina,
Map3k7, Med1, Msx1, Mtap1B, Ngn2, Notch1, TgfβII,
Doublecortin, Protocadherin18, Tgfβρεχεπτορ1, TopoIIβ,
with the latter four genes confirmed also in Experiment I.
Notch3, Nr2f2, Shh, and Tial1, were increased in dissected
neural tube [39] but decreased in whole embryos, indicat-
ing that they may be deregulated in multiple tissues.
Nonetheless, the overlap between results from different
laboratories, despite differences in experimental design,
provides additional validation to our findings.
We cannot currently distinguish which of the changes in
gene expression are in direct response to the diabetic
milieu, and which are indirect changes downstream of
altered transcription factor expression, potentially
increased hypoxia [14] or alterations in yolk sac [40] or
placenta [Salbaum, Kruger, Pavlinkova, Zhang, and Kap-
pen, manuscript submitted]. In this regard, it is interesting
to note that we find no congruence to genes reported as
affected by maternal diabetes in yolk sac of E12 rat
embryos [41]. This indicates not only that both yolk sac
and embryo gene expression are affected by maternal dia-
betes, but that extra-embryonic tissues respond differently
than the embryo proper. It is noteworthy that among the
deregulated genes with known phenotypes in mouse
mutants, over 100 have been reported to be associated
with placental alterations. Even though we have only sur-
veyed the embryo proper, this is suggestive evidence that
placental gene expression may also be altered in diabetic
pregnancies. Our findings are consistent with the idea that
altered gene expression in the embryo, as de-regulated by
maternal diabetes, plays an important role in the patho-
genesis of diabetes-induced birth defects [2,42].
Implications for prevention of adverse outcomes from 
diabetic pregnancies
High glucose levels during critical periods of morphogen-
esis appear to be the major teratogen in diabetic preg-
nancy. In experimental animals, excess glucose is
sufficient to cause dysmorphogenesis of embryos in glu-
cose-injected dams or in whole embryo culture [11,43-
45]. The precise mechanism(s) by which hyperglycemia
induces diabetic embryopathy is(are) not clear, although
involvement of the Glut2 (Slc2a2) transporter has been
demonstrated [45]. Several studies report increased oxida-
tive stress in embryos in a diabetic environment, and the
administration of antioxidants, such as vitamins C or E,
can reduce the occurrence of developmental defects
[13,17,46,47]. Which genes are functionally involved in
these responses in diabetes-exposed embryos, and which
mechanisms provide for the protective effect of anti-oxi-
dant treatment in diabetic embryopathy remains to be
investigated, but it is likely that one or more of the genes
we have identified constitute targets in the antioxidant
response. Similarly, folate supplementation has been
shown to be protective against NTDs in diabetic pregnan-
cies [46,48]. Interestingly, the gene encoding platelet
derived growth factor receptor α (Pdgfrα), mutants of
which exhibit neural tube defects [49], is folate-responsive
in mice [50]. Genes whose expression is altered in diabe-
tes-exposed embryos thus represent excellent candidates
for folate-responsive genes, and may mediate the benefi-




Diabetes was induced in 7–9 week old female FVB mice by
two intraperitoneal injections of 100 mg/kg body weight
Streptozotocin in 50 mM sodium citrate buffer at pH4.5
(STZ; Sigma, St. Louis, MO) within a one-week interval.
The dams were set up for mating no earlier than 7 days
after the last injection, and the day of detection of a vagi-
nal plug was counted as day 0.5 of gestation. We used
embryos only from dams (n = 11) whose blood glucose
levels exceeded 250 mg/dl; average glucose levels were
148 mg/dl(± 18) before STZ treatment, 337 mg/dl(± 79)
on the day of mating, and 528 mg/dl(± 70) on the day of
embryo harvest.
Microarray Analysis
Total RNA was isolated from embryos at embryonic day
10.5 (E10.5) using Trizol® (Invitrogen, Carlsbad, CA). We
processed 2 controls and five diabetes-exposed embryos;
the latter group included two specimen with neural tube
defects (NTD) so as to capture the full phenotype spec-
trum of diabetes-exposure in pregnancy. Individual RNA
samples (5 μg) from whole embryos were reverse tran-
scribed (Invitrogen) and labeled (Affymetrix, Santa Clara,
CA). In Experiment I, samples were individually hybrid-
ized to 7 Affymetrix430A2.0 chips, which were scanned
using a GeneChip3000 scanner; Affymetrix GCOS imag-
ing software was used for quality control. In Experiment
II, equal amounts of RNA prepared from 3 individual
embryos were pooled into one sample; each embryo was
from a different pregnancy and three such pools were con-
structed for a total of 9 control embryos, and independ-
ently, for 9 diabetes-exposed embryos; all embryos were
morphologically normal. Expression levels and "Present",BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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"Marginal", "Absent" flags were determined with default
parameters through comparison of matched and mis-
matched oligonucleotides for the respective gene
sequence.
Statistical analyses were performed using GeneSpring7
(Silicon Genetics, Redwood City, CA) and CyberT
[51]http://cybert.microarray.ics.uci.edu/. We grouped the
data for control embryos and those for diabetes-exposed
embryosm respectively, and filtered results in three steps:
(i) "expression", i.e. "present" or "marginal" in at least
one of seven samples; (ii) "statistical significance"
between control and experimental samples of P < 0.05 in
both CyberT and the t-test in GeneSpring; and (iii) "fold
change", i.e. difference between control and diabetes-
exposed samples of beyond either two-fold or 1.5-fold.
The rationale for employing complementary data analysis
packages and details of data transformation have been
described elsewhere [52].
Of 22690 probe sets present on the arrays http://
www.affymetrix.com/products_services/arrays/specific/
mouse430a_2.affx, 15364 probes exhibited signals in at
least one of the 7 samples, and 302 probe sets differed by
more than two fold between these samples. Of these, 180
probe sets passed the t-test in GeneSpring (P < 0.05;
Welch's test assuming unequal variances; false discovery
rate set at 0.05), and 174 probes yielded P-values below P
< 0.05 in Cyber-T. Permutation of the order of tests (sig-
nificance first, fold-change second) identified differential
signals from 2262 probe sets (Cyber-T), with 575 probes
displaying differences between 1.5 and 2-fold, and 174
probes with differences greater than 2-fold between con-
trols and exposed embryos. Regardless of order of filtering
criteria, identical sets of probes were recovered, thus vali-
dating the analysis process. Between Cyber-T and Gene-
Spring, 145 sets passed both statistical filters, and after
removal of duplicates, 126 genes were found to be differ-
entially expressed above the 2-fold cut-off criterion.
For the second experiment, Affymetrix Mouse 430 2.0
arrays were used, which contain 45101 probe sets http://
www.affymetrix.com/products_services/arrays/specific/
mouse430_2.affx. 29687 probe sets exhibited signals in at
least one of 6 samples; differences reached statistical sig-
nificance at p < 0.05 for 9835 probes in the t-test (P <
0.05; Welch's test assuming unequal variances; false dis-
covery rate set at 0.05) implemented in GeneSpring (GX
version 9). 5915 probe sets exhibited differences greater
than 1.5-fold, with 2796 differentially expressed greater
than 2-fold. Cyber-T identified 13770 probe sets with sta-
tistical significance, of which 3992 exceeded the 1.5-fold
change level, and an additional 4601 exceeded the greater
than 2-fold criterion. After removal of internal controls,
5688 probe sets passed the filtering criteria for statistical
significance in both Cyber-T and GeneSpring and exhib-
ited >1.5-fold change between experimental and control
samples, of which 2634 probe sets were identified with
greater than 2-fold differential expression. Reduction of
duplicates for a given gene was done by judgement call
factoring in signal intensity, P-value, distribution of calls
("Present" was judged as more reliable than "Marginal")
and fold-change; only one entry per gene was retained for
a total of 2231 transcripts with differential expression
greater than 2-fold.
The primary data files are available at the NCBI Gene
Expression Omnibus repository (Accession number
GSE9675).
Quantitative Real-time PCR
Quantitative Real-Time PCR (Q-RT-PCR) using an ABI
Prism7000 instrument was performed as described [53]
on cDNA samples from individual diabetes-exposed
embryos (5 litters) and controls (4 litters), or pools of 4–
5 control embryos from the same litter (4 litters) isolated
at E10.5 (for details, see legend to Table 2). At E9.5, 6 con-
trol and 9 diabetes-exposed embryos were selected from 3
litters each, respectively, and E8.5 embryos were from 4
litters (10 controls) and 5 litters (9 diabetes-exposed
embryos). All embryos used for Q-RT-PCR were morpho-
logically normal. Normalization was done to Polymerase
epsilon 4 (Pole4) cDNA in the same sample; Pole4 levels
were unaffected by maternal diabetes on Experiment I and
Experiment II arrays. Differences between samples (n =
individual embryos except where noted otherwise) were
evaluated for statistical significance using an unpaired
two-tailed t-test. Primers (Additional file 5) were posi-
tioned across exon-exon junctions to exclude amplifica-
tion of potentially contaminating DNA. The amplification
products were designed to originate from a different
region of the mRNA than that detected by probes on the
microarray, in order to provide independent confirmation
of expression measurements.
Annotation for tissue expression, function and mutant 
mouse phenotypes
Information on gene expression in embryos, where avail-
able, was collected from MGI http://www.informat
ics.jax.org. Molecular function attributes were based on
GO-annotation (NetAffx™ https://www.affymetrix.com/
analysis/netaffx/index.affx, updated as of July 21, 2008),
supplemented with information from ENSEMBL and
UCSC genome browsers and PubMed. Information on
mutant phenotypes was obtained from MGI (as of Octo-
ber 21, 2008) for null and conditional alleles.
Transcription factor binding site prediction
Whole Genome rVISTA http://genome.lbl.gov/vista/
index.shtml was used to identify transcription factor bind-BMC Genomics 2009, 10:274 http://www.biomedcentral.com/1471-2164/10/274
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ing sites that are conserved between mouse and human
and are over-represented in the 5 Kb upstream regions of
our maternal diabetes affected genes relative to all 5 Kb
upstream regions in the human genome (P-value <
0.006).
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